(Q82747854)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16520998%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Prescription of rh-APC differs substantially among western European countries (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16520998%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1

Marcus J Schultz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16520998%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Marcel Levi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16520998%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

7 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16520998%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

published in

Intensive Care Medicine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16520998%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16520998%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16520998%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

630-631

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16520998%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00134-006-0075-z

17 January 2020

exact match

0 references

cites work

Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis

1 reference

12 December 2020

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

1 reference

12 December 2020

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

12 December 2020

An economic evaluation of activated protein C treatment for severe sepsis

1 reference

12 December 2020

Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.

1 reference

12 December 2020

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

1 reference

12 December 2020

10.1007/S00134-006-0075-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16520998%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference